



ScinoPharm Management Presentation

Jo Shen, Ph.D.
President & CEO
January 12, 2012

TWSE 1789



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation is ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.



Table of Content

Overview of ScinoPharm

Financial & Operation Results

Business Outlook

Q&A



Overview of ScinoPharm

Mission

- **Maintain dominant position in Specialty API for generic market**
- **Provide API custom synthesis services to new drug development & brand companies**
 - Process R&D and Clinical Supplies leading to future contract manufacturing opportunities of new chemical entities (“NCEs”)
 - Contract Manufacturing of Mature Products
- **Supplying small molecules, peptides, biopharmaceutical services**
 - High Potency
 - High Technological Barriers
 - Patent Non-infringing



Company Overview

- Developed more than 50 generic APIs with 16 launched
- Diversified technologies from small molecules to peptides & proteins
- State-of-the-Art facilities inspected by US FDA and authorities from Japan, Australia, Korea & EU
- 280+ clients, many with long-term supply agreements
- CRO/CMO business served 70+ NCE projects, out of which 3 already approved and launched, 5 in phase III expect to file NDA in the next 2-3 years



Competitive Advantages

- Heavy emphasis on R&D, with 86 patents granted worldwide to 17 inventions
- Combination of cost advantages from China & GMP/IP/EHS compliance in Taiwan
- Rich generic pipeline driven by a large & cost effective R&D infrastructure
- Familiarity with drug development & registration requirements
- Track record of timely and extensive client support
- Existence of a repeat broad & global client base



World Class Facilities

Taiwan

- 6.6 hectares of land, 330K sqft facilities with $>200\text{M}^3$ reactor volume after 2 large product lines expansion
- Six of our production lines are equipped with the special capability to produce APIs used in high-potency sterile injections
- US FDA approved & >200 GMP audits by customers
- Provides comprehensive contract research services for brand drug companies
- Global Market



China

- With nearly 250M^3 reactor volume
- The first phase completed by the end of 2011. The second phase completed by the end of the 2012
- cGMP designed facility for intermediates & high potent API
- Complete capabilities in API development, and manufacturing from small to large scale to aim for global and China generic as well as CRAM (Contract Research And Mfg) markets
- Global market including China




ScinoPharm Biotech



- **Developed lab processes for biosimilars**
- **Host systems includes E. Coli, CHO, Yeast, Insect cells**
- **Full scope development capabilities**
 - Cloning
 - Expression & amplification
 - Fermentation & cell culture
 - Recovery & purification
 - Product characterization
 - Bioassay
- **Invest in Tanvex Biologics, Inc.**
 - U.S. company registered in Delaware
 - Specializes in the development of biosimilars and the provision of CRAM services for biologics



Strong and Broad Customer Base



Strong Generics Product Portfolio


Focus on High Barrier and High Potency Generic API Products

Type	# of Product
Oncological	24
CNS	6
Cardiovascular	3
Hormonal	3
Gastrointestinal	1
Muscle	3
Antiviral	3
Respiratory	1
Peptides	5



Global DMF Filings

Number of DMF filed



ScinoPharm's Strengths in R&D and Product Pipeline Well-Demonstrated by the Annual and Cumulative Number of DMF Filings Globally


Major Products-Top 5 account for 66% of FY2011 sales

API	Indications	2011 projected MKT Share*	# of US DMF/EDMF & other Filings
Docetaxel Anhydrous	Anti-Cancer	38% (WW)	53
Irinotecan HCl	Anti-Cancer	44% (WW)	47
Galantamine HBr	Alzheimer's disease	49% (WW)	36
Paclitaxel	Anti-Cancer	21% (WW)	47
Gemcitabine Hydrochloride	Anti-Cancer	30% (EU)	51

* Source: Newport Global Sales Data



Significant Growth of Main Products



Note: 1. Docetaxel's launch for customer was in Q2, 2011
2. Irinotecan HCl, over 3 years after launch, is settling at around 180-200Kg/Yr





Financial & Operation Results

P&L (consolidated)

US\$K, except EPS

	1-3Q, '11	1-3Q, '10	YOY
Net Sales	96,768	87,419	11%
COGS	(49,230)	(40,563)	21%
Gross Profit	47,537	46,856	1%
SG&A Expense	(20,553)	(17,969)	14%
Operating Income	26,985	28,888	-7%
Non-Operating Income	1,779	1,032	72%
Non-Operating Exp.	(2,624)	(1,925)	36%
Profit before Tax	26,140	27,994	-7%
Income Tax	(4,161)	(4,109)	1%
Net Profit attributable to shareholders	21,911	23,885	-8%
EPS (US\$)	0.036	0.042	-15%

Balance Sheet (consolidated)

US\$K

	Sept. 30, '11		Sept. 30, '10	
Cash and Cash Equivalents	104,813	36%	50,632	23%
Accounts Receivable	21,947	7%	23,420	11%
Inventory	46,042	16%	41,930	19%
Long-Term Investment	6,393	2%	5,043	2%
Fixed Assets	101,687	35%	88,213	40%
Total Assets	294,133	100%	221,150	100%
Current Liabilities	21,359	7%	15,551	7%
L-T Liabilities and Others	875	1%	816	0%
Total Liabilities	22,234	8%	16,367	7%
Stockholders' Equity	271,899	92%	204,783	93%


Cash Flow (consolidated)

US\$K


	1-3Q, '11	1-3Q, '10
Cash and cash equivalents at beginning of year	62,841	23,092
Cash flows from operating activities	30,235	33,348
CAPEX	(15,148)	(7,407)
Long-term investment	-	(5,043)
Repayment of Long Term Loans	-	(29,900)
Issuance of common stock	31,467	37,425
Others	(4,582)	(883)
Cash and cash equivalents at end of year	104,813	50,632

Sales by Business

2010




2011




Oncology Sales vs. Total Sales

2010




2011




Sales by Region

2010



2011





Business Outlook

2012 Product Launch Plan

API	Region	Indications	Brand Marketer	Regional Sales	WW Sales
Argatroban	US	Antithrombotic, Anticoagulant	GSK	\$US 139MM*	\$US 205MM*
Galantamine HBr	EU	Alzheimer's disease	Janssen	\$US 314MM*	\$US 527MM*
Modafinil	US	Antinarcolepsy	Cephalon	\$US 1,078MM*	\$US 1,182MM*
Riluzole	EU	ALS	Sanofi Aventis	\$US 100MM*	\$US 224MM*
Anastrozole	JP	Breast Cancer	Astra Zeneca	\$US 270MM**	\$US 1,109MM*
Levonorgestrel	JP	Oral Contraceptive	Bayer AG	\$US 85MM**	\$US 2,326MM*

Source: * Newport
** IMS Data



Outlook

- Sustain Our Current Leadership Position

Continue developing small molecule oncological injectable APIs and expand into other areas with high technology barriers including Peptides and Biopharmaceutical

- Expand Presences in China

Expansion of API business to timely capture the Chinese market facing increasingly stringent GMP requirement

- Japanese Market Penetration

Establishing strategic partnerships with major pharma companies in Japan and expect to market total 6 products next year

- Vertical Integration

With synergy of our API business, expand into high-entry-barrier formulation business to maximize ROI





Brand Quality with Asian Advantages

www.scinopharm.com

